5th Diabetes Drug Discovery and Development Conference April 19-20 in Boston

"Beyond HbA1c - Are There Better Endpoints for Clinical Trials"

To be discussed at the 5th Diabetes Drug Discovery and Development Conference in Boston, MA on April 19-20, 2012.

Deadline for 10% discount ends on March 19th. Register Today!

A highlight of the 5th Diabetes Drug Discovery and Development Conference, to be held on April 19-20, 2012 in Boston, MA, is the panel discussion "Beyond HbA1c - Are There Better Endpoints for Clinical Trials?" The panel will discuss various topics such as why HbA1c may not be an ideal endpoint for clinical trials and what would it take to achieve a new standardized endpoint for clinical trials.

Guests on the panel discussion include:

• Lane Desborough, Product Strategist at Medtronic
• Claudia Graham, Ph.D., MPH, Vice President of Marketing & Global Access at Dexcom
• James F. List, Vice President of Metabolics, R&D, and Full Development Lead of Dapagliflozin, at Bristol-Myers Squibb
• Solomon Steiner, Chief Executive Officer and Chairman, Founder, Perosphere
• Helena W. Rodbard, MD, FACP, MACE, Medical Director, Endocrine and Metabolic Consultant

Join the discussion with other diabetes experts at the 5th Diabetes Drug Discovery and Development Conference. The conference will bring together the leading experts on diabetes from both industry and academia to discuss novel targets for diabetes, lessons learned from current clinical drug development, and business strategies and opportunities under the current regulatory landscape.

This conference is also part of the 2nd Diabetes Summit which consists of one other conference: 2nd Diabetes Partnering & Deal Making.

Register 2 people at the regular price, bring a 3rd person for free! Use discount code rcdvb.